Management Heart Failure with Preserved Ejection Fraction: A Mini Review

1 Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017;14(10):591-602. https://doi.org/10.1038/nrcardio.2017.65 PMid:28492288 Search in Google Scholar

2 Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021;23(3):352-80. https://doi.org/10.1016/j.cardfail.2021.01.022 PMid:33605000 Search in Google Scholar

3 McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. https://doi.org/10.1093/eurheartj/ehab368 PMid:34447992 Search in Google Scholar

4 Van Aelst LN, Arrigo M, Placido R, Akiyama E, Girerd N, Zannad F, et al. Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion. Eur J Heart Fail. 2018;20(4):738-47. https://doi.org/10.1002/ejhf.1050 PMid:29251818 Search in Google Scholar

5 Omote K, Verbrugge FH, Sorimachi H, Omar M, Popovic D, Obokata M, et al. Central haemodynamic abnormalities and outcome in patients with unexplained dyspnoea. Eur J Heart Fail. 2022;387(12):1089-98. https://doi.org/10.1002/ejhf.2747 PMid:36420788 Search in Google Scholar

6 Kumar AA, Gupta DK. Heart failure with preserved ejection fraction. In: Hayes KM, Dellise NR, editors. Managing Heart Failure in Primary Care: A Case Study Approach. Cham: Springer; 2023. https://doi.org/10.1007/978-3-031-20193-6_7 Search in Google Scholar

7 Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. AHA/ACC/HFSA Guideline for the management of heart failure: A report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation. 2022;145:895-1032. https://doi.org/10.1161/CIR.0000000000001063 Search in Google Scholar

8 Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart failure with preserved ejection fraction: JACC scientific statement. J Am Coll Cardiol. 2023;81(18):1810-34. https://doi.org/10.1016/j.jacc.2023.01.049 PMid:37137592 Search in Google Scholar

9 Desai AS, Lam CS, McMurray JJ, Redfield MM. How to manage heart failure with preserved ejection fraction: Practical guidance for clinicians. JACC Heart Fail. 2023;11(6):619-36. https://doi.org/10.1016/j.jchf.2023.03.011 PMid:37140514 Search in Google Scholar

10 Hibodeau JT, Turer AT, Gualano SK, Ayers CR, Velez-Martinez M, Mishkin JD, et al. Characterization of a novel symptom of advanced heart failure: Bendopnea. JACC Heart Fail. 2014;2(1):24-31. https://doi.org/10.1016/j.jchf.2013.07.009 PMid:24622115 Search in Google Scholar

11 Redfield MM, Borlaug BA. Heart failure with preserved ejection fraction. JAMA 2023;329(10):827-38. https://doi.org/10.1001/jama.2023.2020 PMid:36917048 Search in Google Scholar

12 Reddy YN, Kaye DM, Handoko ML, van de Bovenkamp AA, Tedford RJ, Keck C, et al. Diagnosis of heart failure with preserved ejection fraction among patients with unexplained dyspnea. JAMA Cardiol. 2022;7(9):891-9. https://doi.org/10.1001/jamacardio.2022.1916 PMid:35830183 Search in Google Scholar

13 Jain CC, Borlaug BA. Performance and interpretation of invasive hemodynamic exercise testing. Chest. 2020;158(5):2119-29. https://doi.org/10.1016/j.chest.2020.05.552 PMid:32473950 Search in Google Scholar

14 Solomon SD, Rizkala AR, Lefkowitz MP, Shi VC, Gong JJ, Anavekar N, et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circ Heart Fail. 2018;11(7):e004962. https://doi.org/10.1161/CIRCHEARTFAILURE.118.004962 PMid:29980595 Search in Google Scholar

15 Costanzo MR, Stevenson LW, Adamson PB, Desai AS, Heywood JT, Bourge RC, et al. Interventions linked to decreased heart failure hospitalizations during ambulatory pulmonary artery pressure monitoring. J Am Coll Cardiol Heart Fail. 2016;4(5):333-44. https://doi.org/10.1016/j.jchf.2015.11.011 PMid:26874388 Search in Google Scholar

16 Teramoto K, Teng TH, Chandramouli C, Tromp J, Sakata Y, Lam CS. Epidemiology and clinical features of heart failure with preserved ejection fraction. Card Fail Rev. 2022;8:e27. https://doi.org/10.15420/cfr.2022.06 PMid:35991117 Search in Google Scholar

17 Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263-71. https://doi.org/10.1016/j.jacc.2013.02.092 PMid:23684677 Search in Google Scholar

18 Kawano H, Fuiwara A, Kai H, Kumagai E, Okamoto R, Shibata R, et al. Effects of blood pressure lowering in patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis. Hypertens Res. 2019;42(4):504-13. https://doi.org/10.1038/s41440-019-0216-8 PMid:30948821 Search in Google Scholar

19 Kristensen SL, Jhund PS, Lee MM, Køber L, Solomon SD, Granger CB, et al. Prevalence of prediabetes and undiagnosed diabetes in patients with HFpEF and HFrEF and associated clinical outcomes. Cardiovasc Drugs Ther. 2017;31(5-6):545-9. https://doi.org/10.1007/s10557-017-6754-x PMid:28948430 Search in Google Scholar

20 Lam CS. Diabetic cardiomyopathy: An expression of stage B heart failure with preserved ejection fraction. Diab Vasc Dis Res. 2015;12(4):234-8. https://doi.org/10.1177/1479164115579006 PMid:25908570 Search in Google Scholar

21 Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-61. https://doi.org/10.1056/NEJMoa2107038 PMid:34449189 Search in Google Scholar

22 Kitzman DW, Brubaker P, Morgan T, Haykowsky M, Hundley G, Kraus WE, et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: A randomized clinical trial. JAMA. 2016;315(1):36-46. https://doi.org/10.1001/jama.2015.17346 PMid:26746456 Search in Google Scholar

23 Kitzman DW, Whellan DJ, Duncan P, Pastva AM, Mentz RJ, Reeves GR, et al. Physical rehabilitation for older patients hospitalized for heart failure. N Engl J Med. 2021;385(3):203216. https://doi.org/10.1056/NEJMoa2026141 Search in Google Scholar

24 Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail. 2011;13(1):18-28. https://doi.org/10.1093/eurjhf/hfq121 PMid:20685685 Search in Google Scholar

25 Vaduganathan M, Piccini JP, Camm AJ, Crijns HJ, Anker SD, Butler J, et al. Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: A post-hoc analysis of the ATHENA trial. Eur J Heart Fail. 2022;24(6):1094-101. https://doi.org/10.1002/ejhf.2487 PMid:35293087 Search in Google Scholar

26 Packer DL, Piccini JP, Monahan KH, Al-Khalidi HR, Silverstein AP, Noseworthy PA, et al. Ablation versus drug therapy for atrial fibrillation in heart failure: Results from the CABANA trial. Circulation. 2021;143(14):1377-90. https://doi.org/10.1161/CIRCULATIONAHA.120.050991 PMid:33554614 Search in Google Scholar

27 Vaduganathan M, Docherty DF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, et al. SGLT-2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400(10354):757-67. https://doi.org/10.1016/S0140-6736(22)01429-5 PMid:36041474 Search in Google Scholar

28 Solomon SD, McMurray JJ, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089-98. https://doi.org/10.1056/NEJMoa2206286 PMid:36027570 Search in Google Scholar

29 Solomon SD, McMurray JJ, Anand IS, Ge J, Lam CS, Maggioni AP, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609-20. https://doi.org/10.1056/NEJMoa1908655 PMid:31475794 Search in Google Scholar

30 Solomon SD, Vaduganathan M, Claggett BL, Packer M, Zile M, Swedberg K, et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation 2020;141(5):352-61. https://doi.org/10.1161/CIRCULATIONAHA.119.044586 PMid:31736342 Search in Google Scholar

31 Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation. 2015;131(1):34-42. https://doi.org/10.1161/CIRCULATIONAHA.114.013255 PMid:25406305 Search in Google Scholar

32 Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016;37(5):455-62. https://doi.org/10.1093/eurheartj/ehv464 PMid:26374849 Search in Google Scholar